Detected ·

Cloverleaf Bio

$33M—

Cloverleaf Bio, a biotech developing a new class of cancer therapeutics based on RNA modification research from Yale, raised a $33M oversubscribed seed round with participation from Draper Associates, AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund.

Amount
$33 000 000 USD
Stage
—
Event
Funding round
Detected
2026-10-14 12:16:48 UTC
Signal ID
108baf95-9b8f-4043-97a5-11615a952c3b

As the API returns it

{
  "id": "108baf95-9b8f-4043-97a5-11615a952c3b",
  "created_at": "2026-10-14T12:16:48.667990Z",
  "company_name": "Cloverleaf Bio",
  "company_website_url": "cloverleafbio.com",
  "company_linkedin_url": "https://www.linkedin.com/company/98047595",
  "event_type": "funding",
  "funding_amount": 33000000,
  "funding_currency": "USD",
  "funding_stage": null,
  "message": "*Cloverleaf Bio, a biotech developing a new class of cancer therapeutics based on RNA modification research from Yale, raised a $33M oversubscribed seed round with participation from Draper Associates, AbbVie Ventures, Eli Lilly and Company, and Boehringer Ingelheim Venture Fund.*"
}

Latest rounds